title: [Effectiveness of darbepoietin alfa in anemic patients with chronic kidney disease (CKD) in predialysis period].
abstract: Patients with chronic kidney disease (CKD) often suffer from anemia due to erythropoietin deficiency. Anemia treatment with erythropoietin in patients with chronic kidney disease can effectively maintain hemoglobin target level > 11g/dl. In this study we presented the results of anemia treatment with darbepoietin alfa in 18 patients with chronic kidney disease (3-5 stage of CKD) in predialysis period. After 10 weeks of darbepoietin alfa administration at the dose 10 microg/week, hemoglobin serum level had increased over 11 g/dl in 15 patients. In the 3 patients serum hemoglobin level during the darbepoietin alfa treatment did not increased. Between 15 patients, in 4 after 10 weeks of darbepoietin alfa treatment at the dose 10 microg/week and in 7 after 15 weeks of the treatment at the dose 15 microg/2 weeks hemoglobin serum level had increased over 13 g/dl. After 2 months with out darbepoietin alfa treatment hemoglobin serum level had decreased but still maintain the target level 11 g/dl. darbepoietin alfa was well tolerated. The results of this study demonstrate that darbepoietin alfa administered s.c. once weekly or once other week at a small doses is effective in renal anemia treatment and comfortable for a patients.
authors.affiliation: Katedra i Kliniki Nefrologii, Transplantologii i Chorób Wewnetrznych Akademii Medycznej w Poznaniu.
authors.forename: Maria
authors.initials: M
authors.lastname: Wanic-Kossowska
authors.forename: Andrzej
authors.initials: A
authors.lastname: Tykarski
authors.forename: M
authors.initials: M
authors.lastname: Kobelski
authors.forename: Stanisław
authors.initials: S
authors.lastname: Czekalski
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000068256:Darbepoetin alfa; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000172:deficiency; D005260:Female; D006397:Hematinics / Q000008:administration & dosage*; D006454:Hemoglobins / Q000187:drug effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012044:Regression Analysis; D006435:Renal Dialysis; D016896:Treatment Outcome
chemical_list: D006397:Hematinics; D006454:Hemoglobins; D004921:Erythropoietin; D000068256:Darbepoetin alfa